Reducing the Burden of Idiopathic Hypersomnia: Diagnostic and Treatment Considerations
This online program on idiopathic hypersomnia provides healthcare professionals with an in-depth understanding of this complex sleep disorder, including its pathophysiology, diagnosis, and management strategies. Through expert-led presentations and case-based discussions, participants will gain practical insights to improve patient outcomes in clinical practice.
Specialty Specific Guidance: A Cardiologist’s Guide to Using GLP-1 Receptor Agonists in Patients who are Obese
Patients who are obese or overweight are frequently seen in cardiology for other conditions and weight reduction with GLP-1 RAs can be a useful tool in the cardiologist’s toolbox. Through this program, cardiologists will become more familiar with the data supporting the use of GLP 1 RAs in their patients, identify appropriate patients and potential barriers to adherence, and learn how they can more effectively utilize these therapies in their unique patient population.<br> <img src="https://s3.us-east-1.amazonaws.com/media.gathered.com/author/einstein/obm-logo.png" width=170 alt="Obesity Medicine Association Logo" title="Obesity Medicine Association Logo">
Specialty Specific Guidance: An Endocrinologist’s Guide to Using GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight to Help Optimize Their Metabolic Health
Patients who are living with obesity or overweight may seek care with an endocrinologist for other comorbidities, some of which may be directly linked to their weight. Weight reduction and management using pharmacotherapy, including GLP-1 RAs, can be a useful strategy to help patients improve not only their weight but also their metabolic health. Through this program, endocrinologists will gain a deeper understanding of how they can appropriately select patients who may benefit from GLP-1 RAs, especially if they have other comorbidities, and apply clinical trial findings to everyday patient care. They will also enhance their understanding of strategies which can improve both patient adherence and payor authorization/approval.<br> <img src="https://s3.us-east-1.amazonaws.com/media.gathered.com/author/einstein/obm-logo.png" width=170 alt="Obesity Medicine Association Logo" title="Obesity Medicine Association Logo">
Specialty Specific Guidance: An OB/GYN Professionals Guide to Using GLP-1 Receptor Agonists in Patients with Overweight or Obesity to Optimize Women’s Health Across the Lifespan
Women frequently rely on their OB/GYN as their primary source of healthcare, particularly during their reproductive years. Many of these individuals may be living with overweight or obesity, placing the OB/GYN in a uniquely positioned and trusted role to support healthy weight management and broader metabolic health goals. Pharmacotherapy—including GLP-1 receptor agonists—can be an important tool within a comprehensive, patient-centered approach. Through this program, OB/GYNs will develop a deeper understanding of how to appropriately identify candidates for GLP-1 RA therapy across different stages of the lifespan and will learn strategies to improve patient access, streamline documentation, and optimize payor authorization and approval.<br> <img src="https://s3.us-east-1.amazonaws.com/media.gathered.com/author/einstein/obm-logo.png" width=170 alt="Obesity Medicine Association Logo" title="Obesity Medicine Association Logo">
Specialty Specific Guidance: An Orthopedic Surgeon's Guide to Using GLP-1 Receptor Agonists in Patients who are Obese or Overweight to Optimize Joint Health and Surgical Outcomes
Patients who are obese or overweight are more likely to require joint replacement surgery than their normal weight peers; however, higher BMIs also substantially increase the risks of orthopedic surgery. This increased risk often leads to orthopedic surgeons requiring that their patients lose weight and obtain a BMI of <40 kg/m2 before proceeding with surgery. In previous years, bariatric surgery may have been the only feasible option for these patients, but now anti-obesity medications, like GLP-1 receptor agonists, are a valid alternative and may be more palatable for patients. Through this program, orthopedic surgeons will gain a deeper understanding of how they can appropriately select patients who may benefit from GLP-1 RAs and enhance their understanding of strategies which can improve patient access and adherence.<br> <img src="https://s3.us-east-1.amazonaws.com/media.gathered.com/author/einstein/obm-logo.png" width=170 alt="Obesity Medicine Association Logo" title="Obesity Medicine Association Logo">
The Evolving Landscape of GEP-NETs - From Precise Staging to Novel Treatments and Coordinated Care
Welcome to this curriculum on the diagnosis and management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This program is designed to provide you with the latest strategies for accurately diagnosing, staging, and treating GEP-NETs by integrating pathological grading with advanced imaging and novel systemic therapies. This activity emphasizes a collaborative approach, encouraging multidisciplinary care coordination to personalize treatment plans and optimize outcomes for patients with this complex disease.
Transforming Early-Stage Colorectal Cancer: The Evolving Role of dMMR/MSI-H Testing and Immunotherapy
This curriculum is designed to equip multidisciplinary clinicians with the up-to-date knowledge and skills needed to accurately identify, interpret, and apply dMMR/MSI-H biomarker testing in the management of early and locally advanced colorectal cancer. Through an evidence-based exploration of tumor biology, testing methodologies, guideline updates, and emerging immunotherapy strategies, learners will gain the competence to integrate universal testing into routine workflows and make informed, individualized treatment decisions—particularly as immunotherapy reshapes neoadjuvant and adjuvant paradigms. By completing this curriculum, participants will be better prepared to optimize patient selection, coordinate multidisciplinary care, and improve outcomes for patients with early-stage dMMR/MSI-H colorectal cancer.
Transforming IgAN Management: A Clinical Guide to Diagnosis, Therapeutics, and Multidisciplinary Collaboration
Welcome to our comprehensive learning program on screening, diagnosing, and managing IgA nephropathy (IgAN). This program aims to provide you with a deep understanding of screening techniques, referral procedures, treatment selection, drug distribution and safety and monitoring requirements in IgAN management. Furthermore, this activity encourages care coordination between interdisciplinary team members to improve the co-management of patients with IgAN.
Unleashing Innovation: The Role of Bispecific Antibodies in Managing Diffuse Large B-Cell Lymphoma
This dynamic course focuses on the exchange of best practices regarding the use of bispecifics in patients with R/R DLBCL including patient eligibility. Through this interactive, small-group activity, participants will review brief modules and patient cases to identify signs and symptoms of toxicities experienced while receiving treatment with bispecific antibodies for R/R DLBCL and also integrate protocols to manage CRS and ICANS effectively when managing patients. The group will gather for a live discussion via Zoom to share and exchange ideas on this topic.
